Back to User profile » Dr Sai-Hong Ou
Papers published by Dr Sai-Hong Ou:
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:199-203
Published Date: 25 December 2025
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
Hu Y, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:147-159
Published Date: 31 October 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib
Ou SHI, Park CJ, Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2025, 16:139-145
Published Date: 22 October 2025
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Lung Cancer: Targets and Therapy 2019, 10:125-130
Published Date: 13 November 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Zhu VW, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2019, 10:21-26
Published Date: 12 March 2019
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2018, 9:111-116
Published Date: 8 November 2018
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2017, 8:241-247
Published Date: 6 December 2017
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH, Soo RA
Drug Design, Development and Therapy 2015, 9:5641-5653
Published Date: 15 October 2015
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Ou SH
Drug Design, Development and Therapy 2011, 5:471-485
Published Date: 23 November 2011